Septic encephalopathy and septic encephalitis‬‬

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 2, 2017, Pages 121-132

  Tauber, Simone C ^a   Eiffert, Helmut ^b   Brück, Wolfgang ^b   Nau, Roland ^b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Sleep Laboratory   (Germany)

Author keywords

cognitive impairment; microglial activation; neuroinflammation; Sepsis; septic encelopathy

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADIPONECTIN; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C5A RECEPTOR; DOPAMINE; DROTRECOGIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BIOLOGICAL MARKER; CYTOKINE;

BLOOD BRAIN BARRIER; BRAIN PERFUSION; CAUSE OF DEATH; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CIRCADIAN RHYTHM; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DELIRIUM; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; ENCEPHALITIS; HUMAN; MACROPHAGE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REVIEW; SEPSIS; SEPSIS ASSOCIATED ENCEPHALOPATHY; SEPTIC EMBOLIC ENCEPHALITIS; SEPTIC METASTATIC ENCEPHALITIS; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; BRAIN DISEASES; COMPLICATION; DIAGNOSTIC IMAGING; HOMEOSTASIS; IMMUNOLOGY; INFECTIOUS ENCEPHALITIS; METABOLISM; MORTALITY;

BIOMARKERS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; CYTOKINES; HOMEOSTASIS; HUMANS; INFECTIOUS ENCEPHALITIS; NEUROTRANSMITTER AGENTS; SEPSIS;

EID: 85009494263     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1265448     Document Type: Review

References (129)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States:analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310.
2. Siddiqi N, House AO, Holmes JD., Occurrence and outcome of delirium in medical in-patients:a systematic literature review. Age Ageing. 2006;35(4):350–364.
3. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive Care Med. 2007;33(6):941–950.
4. Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol. 2012;8(10):557–566.
5. Warren HS. Strategies for the treatment of sepsis. New Engl J Med. 1997;336(13):952–953.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. New Engl J Med. 2003;348(2):138–150.
7. Sprung CL, Peduzzi PN, Shatney CH, et al. Impact of encephalopathy on mortality in the sepsis syndrome. The veterans administration systemic sepsis cooperative study group. Crit Care Med. 1990;18(8):801–806.
8. Iwashyna TJ, Ely EW, Smith DM, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–1794.
9. Widmann CN, Heneka MT. Long-term cerebral consequences of sepsis. Lancet Neurol. 2014;13(6):630–636.
10. Mazeraud A, Pascal Q, Verdonk F, et al. Neuroanatomy and physiology of brain dysfunction in sepsis. Clin Chest Med. 2016;37(2):333–345.
11. Salluh JI, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients:systematic review and meta-analysis. BMJ. 2015;350:h2538.
12. Brummel NE, Jackson JC, Pandharipande PP, et al. Delirium in the ICU and subsequent long-term disability among survivors of mechanical ventilation. Crit Care Med. 2014;42(2):369–377.• Recent meta-analysis of outcomes after delirium in critically ill patients during their stay in hospital and after discharge.
13. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
14. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients:validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29(7):1370–1379.
15. European Delirium Association; American Delirium Society. The DSM-5 criteria, level of arousal and delirium diagnosis:inclusiveness is safer. BMC Med. 2014;12:141.
16. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2013;315(8):801–810.
17. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis:for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):762–774.
18. Polito A, Eischwald F, Maho AL, et al. Pattern of brain injury in the acute setting of human septic shock. Crit Care. 2013;17(5):R204.
19. Siami S, Annane D, Sharshar T. The encephalopathy in sepsis. Crit Care Clin. 2008;24(1):67–82.
20. Hosokawa K, Gaspard N, Su F, et al. Clinical neurophysiological assessment of sepsis-associated brain dysfunction:a systematic review. Crit Care. 2014;18(6):674.
21. Berisavac II, Padjen VV, Ercegovac MD, et al. Focal epileptic seizures, electroencephalography and outcome of sepsis associated encephalopathy-a pilot study. Clin Neurol Neurosurg. 2016;148:60–66.
22. Azabou E, Magalhaes E, Braconnier A, et al. Early standard electroencephalogram abnormalities predict mortality in septic intensive care unit patients. PLoS One. 2015;10(10):e0139969.
23. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol. 1993;47(2):169–176.
24. Banks WA, Kastin AJ, Durham DA. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res Bull. 1989;23(6):433–437.
25. Rothwell NJ, Luheshi G. Pharmacology of interleukin-1 actions in the brain. Adv Pharmacol. 1994;25:1–20.
26. Pan W, Kastin AJ. TNF-alpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol. 2002;174(2):193–200.
27. Akrout N, Sharshar T, Annane D. Mechanisms of brain signaling during sepsis. Curr Neuropharmacol. 2009;7(4):296–301.• Overview about how systemic inflammation reaches the central nervous system, i.e. via the disturbed blood–brain barrier, the circumventricular organs or by specific carriers within the blood–brain barrier.
28. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett. 1994;179(1–2):53–56.
29. Sun D, Lytle C, O’Donnell M. IL-6 secreted by astroglial cells regulates Na-K-Cl cotransport in brain microvessel endothelial cells. Am J Physiol. 1997;272(6pt1):C1829–C1835.
30. Miyata S. New aspects in fenestrated capillary and tissue dynamics in the sensory circumventricular organs of adult brains. Front Neurosci. 2015;9:390.
31. Banks WA, Robinson SM. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav Immun. 2010;24(1):102–109.
32. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci. 2003;4(2):103–112.•• Hypothesis paper about how additional systemic inflammation in individuals with neurodegenerative diseases and existing chronic inflammation contributes to disease progression through further activation of microglia.
33. Mayhan WG. Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation:role of inducible nitric oxide synthase. Brain Res. 1998;792(2):353–357.
34. Michels M, Danielski LG, Dal-Pizzol F, et al. Neuroinflammation:microglial activation during sepsis. Curr Neurovasc Res. 2014;11(3):262–270.
35. Lu CX, Qiu T, Tong HS, et al. Peripheral T-lymphocyte and natural killer cell population imbalance is associated with septic encephalopathy in patients with severe sepsis. Exp Ther Med. 2016;11(3):1077–1084.
36. Schramm P, Klein KU, Falkenberg L, et al. Impaired cerebrovascular autoregulation in patients with severe sepsis and sepsis-associated delirium. Crit Care. 2012;16(5):R181.
37. Pfister D, Siegemund M, Dell-Kuster S, et al. Cerebral perfusion in sepsis-associated delirium. Crit Care. 2008;12(3):R63.
38. McGrane S, Girard TD, Thompson JL, et al. Procalcitonin and C-reactive protein levels at admission as predictors of duration of acute brain dysfunction in critically ill patients. Crit Care. 2011;15(2):R78.
39. Hughes CG, Morandi A, Girard TD, et al. Association between endothelial dysfunction and acute brain dysfunction during critical illness. Anesthesiology. 2013;118(3):631–639.
40. Kadoi Y, Saito S. An alteration in the gamma-aminobutyric acid receptor system in experimentally induced septic shock in rats. Crit Care Med. 1996;24(2):298–305.
41. Semmler A, Frisch C, Debeir T, et al. Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol. 2007;204(2):733–740.
42. Jacob A, Brorson JR, Alexander JJ. Septic encephalopathy:inflammation in man and mouse. Neurochem Int. 2011;58(4):472–476.
43. Basler T, Meier-Hellmann A, Bredle D, et al. Amino acid imbalance early in septic encephalopathy. Intensive Care Med. 2002;28(3):293–298.
44. Gunther ML, Morandi A, Ely EW. Pathophysiology of delirium in the intensive care unit. Crit Care Clin. 2008;24(1):45–65.
45. Han L, Mccusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099–1105.
46. Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry. 2000;5(2):132–148.
47. Tsuruta R, Oda Y. A clinical perspective of sepsis-associated delirium. J Intensive Care. 2016;4:18.
48. Gamberini M, Bolliger D, Buse GAL, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery-a randomized controlled trial. Crit Care Med. 2009;37(5):1762–1768.
49. Girard TD, Ware LB, Bernard GR, et al. Associations of markers of inflammation and coagulation with delirium during critical illness. Intensive Care Med. 2012;38(12):1965–1973.
50. Ogino Y, Kaneda K, Nakahara T, et al. Systemic inflammation and delirium in the peri-extubation period of mechanical ventilation:an observational prospective study of intensive care unit patients. Bull Yamaguchi Med School. 2015;62:1–10.
51. Tomasi CD, Vuolo F, Generoso J, et al. Biomarkers of delirium in a low-risk community-acquired pneumonia-induced sepsis. Mol Neurobiol. 2016 Jan 14.
52. van den Boogaard M, Kox M, Quinn KL, et al. Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. Crit Care. 2011;15(6):R297.
53. Ritter C, Tomasi CD, Dal-Pizzol F, et al. Inflammation biomarkers and delirium in critically ill patients. Crit Care. 2014;18 (3):R106.• Overview about the relevance of biomarkers in sepsis-associated delirium.
54. Schwalm MT, Pasquali M, Miguel SP, et al. Acute brain inflammation and oxidative damage are related to long-term cognitive deficits and markers of neurodegeneration in sepsis-survivor rats. Mol Neurobiol. 2014;49(1):380–385.
55. Lemstra AW, Groen in’t Woud JC, Hoozemans JJ, et al. Microglia activation in sepsis:a case-control study. J Neuroinflammation. 2007;4:4.
56. Jackson AC, Gilbert JJ, Young GB, et al. The encephalopathy of sepsis. Can J Neurol Sci. 1985;12(4):303–307.
57. Sharshar T, Annane D, de la Grandmaison GL, et al. The neuropathology of septic shock. Brain Pathol. 2004;14 (1):21–33.•• The only detailed neuropathological study of alterations in septic shock in humans to date.
58. Bitsch A, Nau R, Hilgers RA, et al. Focal neurologic deficits in infective endocarditis and other septic diseases. Acta Neurol Scand. 1996;94(4):279–286.
59. Prange HW. Septic focal encephalitis. Intensivmed. 2006;43:85–93.
60. Pruitt AA, Rubin RH, Karchmer AW, et al. Neurological complications of bacterial endocarditis. Medicine. 1978;57(4):329–343.
61. Tauber SC, Bunkowski S, Brück W, et al. Septic metastatic encephalitis:coexistence of brain damage and repair. Neuropathol Appl Neurobiol. 2011;37(7):768–776.
62. Schwechheimer K, Hashemian A. Neuropathologic findings after organ transplantation. An autopsy study. Gen Diagn Pathol. 1995;141(1):35–39.
63. Barichello T, Martins MR, Reinke A, et al. Behavioral deficits in sepsis-surviving rats induced by cecal ligation and perforation. Braz J Med Biol Res. 2007;40(6):831–837.
64. Semmler A, Hermann S, Mormann F, et al. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008;5:38.
65. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2016. pii:S0889-1591(16)30055-1.
66. Morgan BP, Gasque P. Expression of complement in the brain:role in health and disease. Immunol Today. 1996;17(10):461–466.
67. Jacob A, Hensley LK, Safratowich BD, et al. The role of the complement cascade in endotoxin-induced septic encephalopathy. Lab Invest. 2007;87(12):1186–1194.
68. Nadeau S, Rivest S. The complement system is an integrated part of the natural innate immune response in the brain. FASEB J. 2001;15(8):1410–1412.
69. Gasque P, Singhrao SK, Neal JW, et al. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol. 1997;150(1):31–41.
70. Crane JW, Buller KM. Systemic blockade of complement C5a receptors reduces lipopolysacharride-induced responses in the paraventricular nucleus and the central amygdala. Neurosci Lett. 2007;424(1):10–15.
71. Flierl MA, Stahel PF, Rittirsch D, et al. Inhibition of complement C5a prevents breakdown of the blood-brain-barrier and pituitary dysfunction in experimental sepsis. Crit Care. 2009;13:R12.
72. Li S, Boackle SA, Holers VM, et al. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation. 2005;12(2):67–80.
73. Mukherjee P, Thomas S, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation. 2008;5:5.
74. Chen Q, Yu W, Shi J, et al. Insulin alleviates the inflammatory response and oxidative stress injury in cerebral tissues in septic rats. J Inflamm. 2014;11:18.
75. Barichello T, Machado RA, Constantino L, et al. Antioxidant treatment prevented late memory impairment in an animal model of sepsis. Crit Care Med. 2007;35(9):2186–2190.
76. Toklu HZ, Uysal MK, Kabasakal L, et al. The effects of riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats. J Surg Res. 2009;152(2):238–248.
77. Vincent JL, Privalle CT, Singer M, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX). Crit Care Med. 2015;43(1):57–64.
78. Grover R, Zaccardelli D, Colice G, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome international septic shock study group. Crit Care Med. 1999;27(5):913–922.
79. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88:effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21–30.
80. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38(8):1685–1694.
81. Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with gram-negative sepsis. Crit Care Med. 2003;31(2):419–427.
82. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med. 2003;31(2):367–373.
83. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Intern Med. 1994;121(1):1–5.
84. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis:a randomized controlled trial. E5 study investigators. JAMA. 2000;283(13):1723–1730.
85. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. Tnf-alpha mab sepsis study group. JAMA. 1995;273(12):934–941.
86. Cohen J, Carlet J. INTERSEPT:an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med. 1996;24(9):1431–1440.
87. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet. 1998;351(9107):929–933.
88. Opal SM, Fisher CJ, Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis:a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med. 1997;25(7):1115–1124.
89. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour:results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749–1755.
90. Volbeda M, Wetterslev J, Gluud C, et al. Glucocorticosteroids for sepsis:systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015;41(7):1220–1234.
91. Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis:the HYPRESS randomized clinical trial. JAMA. 2016;316(17):1775–1785.
92. COIITSS Study Investigators, Annane D, Cariou A, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults:a randomized controlled trial. JAMA 2010; 303 (4):341–348.
93. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015;(12):CD002243.
94. Póvoa P, Salluh JI, Martinez ML, et al. Clinical impact of stress dose steroids in patients with septic shock:insights from the PROWESS-shock trial. Crit Care. 2015;19:193.
95. Arabi YM, Aljumah A, Dabbagh O, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock:a randomized controlled trial. CMAJ. 2010;182(18):1971–1977.
96. Kress JP. Clinical trials of early mobilization of critically ill patients. Crit Care Med. 2009;37(10 Suppl):S442–S447.
97. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients:a randomised controlled trial. Lancet. 2009;373(9678):1874–1882.
98. Page VJ, Davis D, Zhao XB, et al. Statin use and risk of delirium in the critically ill. Am J Respir Crit Care Med. 2014;189(6):666–673.
99. Morandi A, Hughes CG, Thompson JL, et al. Statins and delirium during critical illness:a multicenter, prospective cohort study. Crit Care Med. 2014;42 (8):1899–1909.• One of the clinical trials investigating beneficial effects of statins in sepsis-associated delirium.
100. Needham DM, Colantuoni E, Dinglas VD, et al. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome:an ancillary study to a randomised controlled trial. Lancet Respir Med. 2016;4(3):203–212.
101. Dinglas VD, Hopkins RO, Wozniak AW, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome:prospective follow-up of SAILS randomised trial. Thorax. 2016;71(5):401–410.
102. Casarin A, McAuley DF, Alce TM, et al. Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial):study protocol for a randomized controlled trial. Trials. 2015;16:218.
103. Gao R, Tang YH, Tong JH, et al. Systemic lipopolysaccharide administration-induced cognitive impairments are reversed by erythropoietin treatment in mice. Inflammation. 2015;38(5):1949–1958.
104. Li R, Tong J, Tan Y, et al. Low molecular weight heparin prevents lipopolysaccharide induced-hippocampus-dependent cognitive impairments in mice. Int J Clin Exp Pathol. 2015;8(8):8881–8891.
105. Zhu SZ, Huang WP, Huang LQ, et al. Huperzine A protects sepsis associated encephalopathy by promoting the deficient cholinergic nervous function. Neurosci Lett. 2016;631:70–78.
106. Gao R, Kan MQ, Wang SG, et al. Disrupted tryptophan metabolism induced cognitive impairment in a mouse model of sepsis-associated encephalopathy. Inflammation. 2016;39 (2):550–560.• A study showing that treatment with IDO inhibitor 1-methyl-D, L-tryptophan protected mice from sepsis-induced cognitive impairment in a sepsis model.
107. Imamura Y, Wang H, Matsumoto N, et al. Interleukin-1β causes long-term potentiation deficiency in a mouse model of septic encephalopathy. Neuroscience. 2011;187:63–69.
108. Sui D-M, Xie Q, Yi W-J, et al. Resveratrol protects against sepsis-associated encephalopathy and inhibits the NLRP3/IL-1β axis in microglia. Mediators Inflamm. 2016;2016:1–10.
109. Ritter C, Andrades M, Frota Júnior ML, et al. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med. 2003;29(10):1782–1789.
110. Michels M, Danieslki LG, Vieira A, et al. CD40-CD40 ligand pathway is a major component of acute neuroinflammation and contributes to long-term cognitive dysfunction after sepsis. Mol Med. 2015;21:219–226.
111. Wilson JX, Wu F. Vitamin C in sepsis. Subcell Biochem. 2012;56:67–83.
112. Yokoo H, Chiba S, Tomita K, et al. Neurodegenerative evidence in mice brains with cecal ligation and puncture-induced sepsis:preventive effect of the free radical scavenger edaravone. PLoS One. 2012;7(12):e51539.
113. Hernandes MS, D’Avila JC, Trevelin SC, et al. The role of Nox2-derived ROS in the development of cognitive impairment after sepsis. J Neuroinflammation. 2014;11:36.
114. Zhou TF, Yu JG. Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia. J Surg Res. 2013;183(1):304–312.
115. Wang GB, Ni YL, Zhou XP, et al. The AKT/mTOR pathway mediates neuronal protective effects of erythropoietin in sepsis. Mol Cell Biochem. 2014;385(1–2):125–132.
116. Michels M, Vieira AS, Vuolo F, et al. The role of microglia activation in the development of sepsis-induced long-term cognitive impairment. Brain Behav Immun. 2014;43:54–59.
117. Wu J, Zhang M, Hao S, et al. Mitochondria-targeted peptide reverses mitochondrial dysfunction and cognitive deficits in sepsis-associated encephalopathy. Mol Neurobiol. 2015;52 (1):783–791.• Focus on the role of microglia and the cellular mechanisms that activate these cells during sepsis and the impact on cognitive performance.
118. Huang M, Liu C, Hu Y, et al. Gamma-secretase inhibitor DAPT prevents neuronal death and memory impairment in sepsis associated encephalopathy in septic rats. Chin Med J (Engl). 2014;127(5):924–928.
119. Fang J, Lian Y, Xie K, et al. Epigenetic modulation of neuronal apoptosis and cognitive functions in sepsis-associated encephalopathy. Neurol Sci. 2014;35(2):283–288.
120. Wu J, Dong L, Zhang M, et al. Class I histone deacetylase inhibitor valproic acid reverses cognitive deficits in a mouse model of septic encephalopathy. Neurochem Res. 2013;38(11):2440–2449.
121. Esen F, Erdem T, Aktan D, et al. Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis:a randomized controlled experimental study. Crit Care. 2005;9(1):R18–R23.
122. Spapen H, Nguyen DN, Troubleyn J, et al. Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock. Crit Care. 2010;14(2):R54.
123. Mussack T, Briegel J, Schelling G, et al. Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock. Clin Chem Lab Med. 2005;43(3):259–268.
124. Mussack T, Briegel J, Schelling G, et al. Hemofiltration does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo. Eur J Med Res. 2005;10(2):81–87.
125. Nau R, Djukic M, Spreer A, et al. Bacterial meningitis:an update of new treatment options. Expert Rev Anti Infect Ther. 2015;13(11):1401–1423.
126. Mascalchi M, Vella A. Magnetic resonance and nuclear medicine imaging in ataxias. Handb Clin Neurol. 2012;103:85–110.
127. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. Med Klin Intensivmed Notfmed. 2016;111(5):417–424.
128. Albrecht DS, Granziera C, Hooker JM, et al. In vivo imaging of human neuroinflammation. ACS Chem Neurosci. 2016;7 (4):470–483.• Overview on new methods to image neuroinflammation in the human central nervous system.
129. Adam N, Kandelman S, Mantz J, et al. Sepsis-induced brain dysfunction. Expert Rev Anti Infect Ther. 2013;11(2):211–221.